N@N

Watson Pharmaceuticals: Watson to Present at the Bank of America Merrill Lynch Global Healthcare Conference

^{Published on 2009-09-08 13:17:15 - Market Wire}
 

MORRISTOWN, NJ--(Marketwire - September 8, 2009) - Watson Pharmaceuticals, Inc. (NYSE: [ WPI ]), a leading specialty pharmaceutical company, today announced that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch Global Healthcare Conference on Tuesday, September 15, 2009 at 2:30 p.m. (BST) (9:30 a.m. EDT).

This presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Web site at [ http://ir.watson.com ]. The webcast can also be accessed at the following URL: [ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=WPI&item_id=2423784 ].

An archived version will be available for 30 days after the live presentation and can be accessed at the same locations.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical. For press release and other company information, visit Watson Pharmaceuticals' Web site at [ http://www.watson.com ].

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.